VolitionRx Limited (VNRX) is a Henderson, Nevada-based epigenetics company that commercializes blood tests built on its Nu.Q nucleosome platform, spanning veterinary cancer screening, sepsis-related NETosis assays, and human cancer monitoring. Its shares were changing hands at $0.198 at mid-morning on Monday, down 13.91% from the previous session's close of $0.230, confirming a clear downward direction. No new company news explains the drop. The move is best read as a give-back of Friday's 24.66% post-earnings surge, with the same funding and dilution concerns that have capped previous rallies reasserting themselves.
Friday's session was the catalyst that set up Monday. VolitionRx reported third-quarter 2026 results before the bell on Friday, disclosing revenue of roughly $1.6 million against $0.6 million a year earlier — a 157% increase that beat consensus of about $0.7 million. Operating expenses fell 14%, the operating loss narrowed 35% to $3.3 million, and the net loss improved to $3.8 million from $5.4 million. Management also highlighted a letter of intent with Missionpharma, part of the Toyota Tsusho group, aimed at point-of-care sepsis testing in resource-constrained markets, and a French government-funded sepsis program in which the company's assay is the sole biomarker.
Investors rewarded the update with a 24.66% jump to $0.230 on 56.9 million shares, a heavy turnover day for a company this size. That gain left the stock extended in the short term, and Monday's decline is consistent with routine profit-taking. Even after the pullback, shares remain roughly 7% above the $0.1845 close recorded before the results, which frames the session as consolidation rather than a fundamental repricing.
The ceiling on the rally remains financial rather than scientific. VolitionRx ended September with about $2.4 million in cash and used $4.6 million of cash in operations during the quarter, against $15 million over the first nine months of the year. The company has also said its plans do not alleviate substantial doubt about its ability to continue as a going concern, and it remains out of compliance with the NYSE American stockholders' equity listing standard, with time to regain compliance extending into 2027.
That funding picture is being managed by selling equity. VolitionRx raised roughly $5.2 million net through its at-the-market program during the third quarter and issued nearly ten million shares to settle convertible notes. With no revenue guidance for 2026 and management flagging that sales will remain lumpy, investors have repeatedly treated sharp spikes as opportunities to exit. Monday's action fits that pattern precisely.
The move is idiosyncratic. Broad equity benchmarks were down about 1.3% at mid-morning while the healthcare sector traded slightly higher, so the 13.91% decline is driven by stock-specific positioning, not sector sympathy or macro news. Volume tells a similar story: roughly 0.43 million shares changed hands in the first 70 minutes, above the approximately one million shares per session that recent weeks averaged on a full-day basis, but far below Friday's 56.9 million. This looks like post-event churn among retail and short-term traders rather than institutional distribution.
Technically, the stock has slipped back below its 50-day moving average near $0.23 and remains light years from its 200-day average around $1.90. It also lost the $0.20 round-number level during the morning, with the 52-week low of $0.1564, set in late October, the obvious reference point below.
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news paired with an extreme, rare price swing. VolitionRx earns 35 out of 100.
The verified news is moderate: a strong revenue beat on a small base, a narrower loss, and a credible commercial partner, but no guidance and no licensing deal signed. The price move is also modest relative to this stock's own behavior. The 13.91% decline was about 2.4 times the 5.8% average absolute daily move of the past 69 sessions, and moves of similar size occurred three times in that stretch — including a 24.66% gain just one session earlier. Solid news and an unremarkable relative swing combine into a mid-range score.
Attention now shifts to catalysts that could convert science into cash. Investors are watching for publication of the peer-reviewed feline lymphoma study, which is a condition for unlocking a $5 million milestone payment, and for the French reimbursement submission for the Nu.Q Lung Cancer test, with routine clinical use targeted for the first half of 2027. Progress on the Missionpharma letter of intent, an IVDR application in Europe, and licensing talks around Capture-Seq technology are also in focus. Fourth-quarter results are expected around late March 2027, with analysts projecting revenue near $0.7 million.
The principal risks are unchanged: a thin cash runway, continued reliance on equity sales, unpredictable revenue recognition, thin analyst coverage, and listing-standard compliance. Any delay to the milestone payment or reimbursement timeline would likely be met with another wave of selling.
Investors looking to systematize their approach can explore Tickeron's Trending AI Robots page. Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but this curated section highlights only those strategies performing strongest under present market conditions. Bots differ widely by strategy logic, holding period, performance metrics, and the symbols they trade, so the list offers a practical starting point for matching a methodology to your own objectives. Review the current leaders and see which setups align with your approach.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where VNRX advanced for three days, in 146 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where VNRX's RSI Oscillator exited the oversold zone, 26 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 46 cases where VNRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VNRX as a result. In 90 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
VNRX moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VNRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
VNRX broke above its upper Bollinger Band on November 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for VNRX entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.183) is normal, around the industry mean (4.142). P/E Ratio (-0.051) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.767) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. VNRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VNRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a development stage life sciences company
Industry MedicalNursingServices